

1 **Small RNA signatures of the anterior cruciate ligament from patients with knee**
2 **joint osteoarthritis**

3 Yalda A. Kharaz^{1,2}, Yongxiang Fang³, Tim Welting⁴, Mandy Peffers^{1,2} *, Eithne J.
4 Comerford^{1,2,5} *

5

6 ¹Department of Musculoskeletal Biology I, Institute of Life Course and Medical
7 Sciences, University of Liverpool, William Duncan Building, Liverpool, UK

8 ²The MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal
9 Ageing (CIMA), Liverpool, UK

10 ³Centre for Genomic Research, Institute of Integrative Biology, Biosciences Building,
11 Crown Street, University of Liverpool, Liverpool L69 7ZB, UK

12 ⁴Department of Orthopaedic Surgery, Maastricht University Medical Centre, 6202 AZ
13 Maastricht, The Netherlands

14 ⁵Institute of Veterinary and Ecological Sciences, Leahurst Campus, University of
15 Liverpool, Neston, UK

16

17 *Correspondence to: Yalda Ashraf Kharaz

18 Tel: 0151 7956100 Email: Y. Ashraf-Kharaz@liverpool.ac.uk

19 Department of Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, 6
20 West Derby Street, Liverpool, L7 8TX

21

22

23 * These authors have contributed equally to this manuscript.

24

25 Keywords: snoRNAs, microRNAs, anterior cruciate ligament, osteoarthritis and small
26 non-coding RNAs

27

28 **ABSTRACT**

29 The anterior cruciate ligaments are susceptible to degeneration, resulting in pain,
30 reduced mobility and development of the degenerative joint disease osteoarthritis.
31 There is currently a paucity of knowledge on how anterior cruciate ligament
32 degeneration and disease can lead to osteoarthritis. Small non-coding RNAs
33 (sncRNAs), such as microRNAs, and small nucleolar RNA, are important regulators
34 of gene expression. We aimed to identify sncRNA profiles of human anterior cruciate
35 ligaments to provide novel insights into their roles in osteoarthritis.

36 RNA was extracted from the anterior cruciate ligaments of non-osteoarthritic knee
37 joints (control) and end-stage osteoarthritis knee joints, used for small RNA
38 sequencing and significantly differentially expressed sncRNAs defined. Bioinformatic
39 analysis was undertaken on the differentially expressed miRNAs and their putative
40 target mRNAs to investigate pathways and biological processes affected.

41 Our analysis identified 184 sncRNA that were differentially expressed between control
42 ACLs derived from osteoarthritic joints with a false discovery adjusted p value<0.05;
43 68 small nucleolar RNAs, 26 small nuclear RNAs and 90 microRNAs. We identified
44 both novel and previously identified (miR-206, -101, -365 and -29b and -29c)
45 osteoarthritis-related microRNAs and other sncRNAs (including SNORD74,
46 SNORD114, SNORD72) differentially expressed in ligaments derived from
47 osteoarthritic joints. Significant cellular functions deduced by the differentially

48 expressed miRNAs included differentiation of muscle ($P < 0.001$), inflammation
49 ($P < 1.42E-10$), proliferation of chondrocytes ($P < 0.03$), fibrosis ($P < 0.001$) and cell
50 viability ($P < 0.03$). Putative mRNAs were associated with the canonical pathways
51 'Hepatic Fibrosis Signalling' ($P < 3.7E-32$), and 'Osteoarthritis' ($P < 2.2E-23$). Biological
52 processes included apoptosis ($P < 1.7E-85$), fibrosis ($P < 1.2E-79$), inflammation
53 ($P < 3.4E-88$), necrosis ($P < 7.2E-88$) and angiogenesis ($P < 5.7E-101$).

54 SncRNAs are important regulators of anterior cruciate disease during osteoarthritis
55 and may be used as therapeutic targets to prevent and manage anterior cruciate
56 ligament disease and the resultant osteoarthritis.

57

58

59 **INTRODUCTION**

60 Ligaments are resilient connective tissues essential for bone-to-bone connections
61 within joints [1]. The anterior cruciate ligament (ACL) is the most commonly damaged
62 ligament [2] with an incidence of approximately 68.6 ACL ruptures per 100,000 people
63 [3] resulting in considerable social and economic costs [4, 5]. In the USA alone, there
64 are approximately 100,000-175,000 ACLs surgeries per year, with cost exceeding of
65 2 billion dollars [6, 7]. ACL injuries can also lead to significant functional impairment in
66 athletes, muscle atrophy and weakness, joint instability, meniscal lesions, and are
67 associated with development of osteoarthritis (OA) [8, 9]. In the case of the knee joint,
68 more than 50% of ACL injury patients eventually develop OA with the degree and
69 progression of disease being accelerated in these cases [10, 11]. Reports
70 demonstrate that there is an association between ACL degeneration and subsequent
71 knee OA, suggesting the importance of ACL degradation in OA pathogenesis [12].

72

73 There is currently substantial interest in the area of epigenetic regulation in ageing,
74 disease, and repair mechanisms in musculoskeletal tissues such as muscle [13, 14],
75 cartilage [15, 16], tendon [17, 18] and ligament [19, 20]. Epigenetics is the study of
76 changes in gene expression that do not derive from changes to the genetic code itself
77 [21]. Insufficient exploration of the epigenetic changes in diseased ACL has been
78 undertaken. One class of epigenetic molecules are small non-coding RNAs (sncRNAs)
79 which include microRNAs (miRNAs or miRs), small nucleolar RNAs (snoRNAs) and
80 small nuclear RNAs (snRNAs) These are functional RNA molecules that are
81 transcribed from DNA but do not translate into proteins and are emerging as important
82 regulators of gene expression before and after protein transcription. Their aberrant
83 expression profiles in musculoskeletal conditions such as ACL injury are expected to
84 be associated with cellular dysfunction and disease development [22]. We have
85 previously identified changes in the sncRNA profiles in ageing and OA human and
86 equine cartilage [16, 23, 24], ageing human and equine tendon [25, 26] and ageing
87 and OA murine joints and serum [27]. Identifying sncRNAs associated with ACL
88 degradation and comprehending their role in OA could have an enormous impact on
89 the understanding of its pathogenesis and future management.

90

91 To date, little is known about the sncRNA changes in diseased ACL. We hypothesise
92 that sncRNA expression is altered in ACLs derived from OA joints and that their
93 identification may elucidate the underlying mechanisms of ACL degeneration. This
94 information could then provide potential diagnostic markers and enable future
95 therapeutic targets to treat ACL degeneration, facilitating prompt positive intervention
96 in the associated development of OA.

97

98 **MATERIALS AND METHODS**

99 All reagents were from ThermoFisher Scientific, unless otherwise stated.

100 **Sample collection**

101 ACLs from non-OA, apparently healthy knee joints (control) (n=4) were obtained from
102 a commercial biobank (Articular Engineering). Ethical approval for the purchase
103 human ACL tissue was granted by the Central University Research Ethics Committee
104 C, University of Liverpool (RETH4721). Diseased OA ACLs were obtained from the
105 knee joints of patients undergoing total knee arthroplasty for end-stage OA treatment
106 (n=4). Fully informed patient consent was given for the use of these samples under
107 the institutional ethical approval (Maastricht University Medical Centre approval IDs:
108 MUMC 2017-0183). Samples were collected in RNAlater and stored at -80°C until
109 used.

110

111 **RNA extraction**

112 RNA was extracted from ACL tissues once pulverised into a powder with a
113 dismembranator (Mikro-S, Sartorius, Melsungen, Germany) under liquid nitrogen.
114 Total RNA was extracted using the miRNeasy kit (Qiagen, Manchester, UK) according
115 to the manufacturer's instructions. The RNA samples were quantified using a
116 Nanodrop spectrophotometer (NanoDrop Technologies, Wilmington, USA). The
117 integrity of the RNA was assessed on the Agilent 2100 Bioanalyzer (Agilent, Stockport,
118 UK) using an RNA Pico chip (Agilent, Stockport, UK).

119

120 **Small RNA-Sequencing analysis: cDNA library preparation and sequencing**

121 1000ng RNA per sample was submitted for library preparation using NEBNext® Small
122 RNA Library Prep Set for Illumina (New England Biosciences (NEB), Ipswich, USA)
123 but with the addition of a Cap-Clip™ Acid Pyrophosphatase (Cell script, Madison,
124 USA) step to remove any 5' cap structures on some snoRNAs [27] and size selected
125 using a range 120-300bp (including adapters). This enabled both miRNAs and
126 snoRNAs to be identified using a non-biased approach. The pooled libraries were
127 sequenced on an Illumina HiSeq4000 platform with version 1 chemistry to generate 2
128 x 150 bp paired-end reads.

129

130 **Data processing**

131 Sequence data were processed through a number of steps to obtain non-coding RNA
132 expression values including; basecalling and de-multiplexing of indexed reads using
133 CASAVA version 1.8.2; adapter and quality trimming using Cutadapt version 1.2.1 [28]
134 and Sickle version 1.200 to obtain fastq files of trimmed reads; aligning reads to human
135 genome reference sequences (release 95) from Ensembl using Tophat version 2.0.10
136 [29] with option “-g 1”; counting aligned reads using HTSeq-count [30] against the
137 features defined in human genome GTF file (release 95). The features whose biotype
138 belonged to the gene categories such as miRNA, snoRNA, and snRNA were
139 extracted.

140 Differential expression (DE) analysis was performed in R using package DESeq2 [31].

141 The processes and technical details of the analysis include; assessing data variation
142 and detecting outlier samples through comparing variations of within and between

143 sample groups using principle component analysis (PCA) and correlation analysis;
144 handling library size variation using DESeq2 default method; formulating data variation
145 using negative binomial distributions; modelling data using a generalised linear model;
146 computing log fold change (logFC) values for control versus OA ACLs based on model
147 fitting results through contrast fitting approach, evaluating the significance of estimated
148 logFC values by Wald test; adjusting the effects of multiple tests using false discovery
149 rate (FDR) [32] approach to obtain FDR adjusted P-values.

150

151 **Pathway analysis of differentially expressed miRNAs and their predicted targets**

152 Potential biological associations of the DE miRNAs in OA ACL were identified using
153 Ingenuity Pathway Analysis (IPA) (IPA, Qiagen Redwood City, USA) 'Core Analysis'.
154 Additionally in order to identify putative miRNA targets, bioinformatic analysis was
155 performed by uploading DE miRNA data into the MicroRNA Target Filter module within
156 IPA. This identifies experimentally validated miRNA-mRNA interactions from TarBase,
157 miRecords, and the peer-reviewed biomedical literature, as well as predicted miRNA-
158 mRNA interactions from TargetScan. We applied a conservative filter at this point,
159 using only experimentally validated and highly conserved predicted mRNA targets for
160 each miRNA. Targets were also filtered on the cells fibroblasts and mesenchymal stem
161 cells (as these were closest to potential cell types within ligament). 'Core Analysis' was
162 then performed in IPA on the filtered mRNA target genes and their associated
163 miRNAs. For each core analysis canonical pathways, novel networks, diseases and
164 functions, and common upstream regulators were queried.

165

166 Additionally TOPP Gene [33] was used for overrepresentation analysis of the mRNA
167 targets from Target Filter using Fisher's Exact test with FDR correction. This tests
168 whether the input mRNAs associate significantly with specific pathways and generates
169 a list of biological process gene ontology (GO) terms. Terms with FDR adjusted $P <$
170 0.05 were summarised using REViGO [34] with allowed similarity of 0.4 and visualised
171 using Cytoscape [35].

172

173 **Statistical analysis**

174 The heatmap, volcano and principle component analysis (PCA) plots were made
175 using MetaboAnalyst 3.5 (<http://www.metaboanalyst.ca>) which uses the R package of
176 statistical computing software.30 [36].

177

178 **RESULTS**

179 **Sample assessment**

180 The ages of the control group (age, mean \pm standard deviation (48 ± 2.16)) and ACLs
181 derived from OA joints (74.7 ± 5.42) were significantly different ($p < 0.05$)
182 (Supplementary Figure 1). Summary of all donors' information is provided in
183 Supplementary Table 1.

184

185 **Analysis of small RNA sequencing data**

186 We identified a total 590 miRNAs, 226 snoRNAs and 100 small nuclear (snRNAs) in
187 the samples (with greater than 10 counts per million (CPM) in each samples). There
188 were 184 differentially expressed sncRNAs identified ($FDR < 0.05$) and at least 10 CPM
189 in each sample. The categories of RNA identified are in Figure 1A and included

190 miRNAs, snoRNAs and small nuclear RNAs (snRNAs). PCA revealed that the ACLs
191 derived from non-OA joints (control) were clustered together and could be clearly
192 separated from the ACLs derived from OA knee joints (Figure 1B).

193

194 Of the 184 snRNAs there were 68 DE snoRNAs (64 reduced in OA and 4 increased
195 in OA), 26 DE snRNAs (24 reduced in OA and 2 increased in OA) and 90 DE miRNAs
196 (43 reduced in OA and 47 increased in OA) (FDR<0.05 and greater than 10 CPM in
197 all samples) (Figure 1C, Supplementary Table 2). The most DE miRNAs are in Table
198 1, with snRNA and snoRNAs in Table 2. We further generated a heatmap of the DE
199 sncRNAs for miRNAs (Figure 1D) and snRNAs and snoRNAs (Supplementary Figure
200 2).

201

202 **Pathway analysis of differentially expressed miRNAs**

203 To explore potential biological associations of the 90 DE miRNAs in ACLs derived from
204 OA knee joints we undertook an IPA 'Core Analysis'. Network-eligible molecules were
205 overlaid onto molecular networks based on information from Ingenuity Pathway
206 Knowledge Database. Networks were then generated based on connectivity.
207 Interesting features were determined from the gene networks inferred. Significant
208 cellular functions deduced by the DE miRNAs included differentiation of muscle
209 (P<0.001), inflammation (P<1.42E-10), proliferation of chondrocytes (P<0.03), fibrosis
210 (P<0.001) and cell viability (P<0.03) (Figure 2A). The top scoring network identified
211 was 'Organismal Injury and Abnormalities' (score 43) and included OA-related
212 miRNAs such as miR-206, miR-101, let-7f, miR-455, miR-29b and miR-29c (Figure
213 2B).

214

215 **Pathway analysis on target mRNA genes of the differentially expressed miRNAs**

216 Next, we undertook analysis to determine the mRNA targets of the DE miRNAs. 90
217 miRNAs that were DE in ACLs derived from OA knee joints compared to controls were
218 initially input into MicroRNA Target Filter. Once a conservative filter was applied (only
219 miRNAs with experimental or highly predicted targets), 529 mRNAs were putative
220 targets (Supplementary Table 3). These mRNAs were then input into IPA core analysis
221 and all results summarised in Supplementary Table 3. The top canonical pathways for
222 target mRNAs of DE miRNAs in OA ACL are in Table 3. Two of the most significant of
223 which were the osteoarthritis pathway ($P < 2.3E-23$) and hepatic fibrosis ($P < 3.1E-32$)
224 (Figure 3). The most significant upstream regulators of these mRNAs included tumour
225 necrosis factor ($P < 1.3E-101$) and transforming growth factor β (TGF β) ($P < 8.5E-83$)
226 (Table 4). Upstream regulators represent molecules that may be responsible for the
227 putative mRNAs in our dataset and cover the gamut of molecule types found in the
228 literature, from transcription factors, to cytokines, chemicals and drugs. The most
229 significant diseases and biological functions identified are shown in Table 5. The top
230 networks identified are in Supplementary Table 3. The network 'cellular development,
231 movement and genes expression' (score 41) (Figure 4A) was overlaid with significant
232 biological processes including apoptosis ($P < 1.7E-85$), fibrosis ($P < 1.2E-79$),
233 inflammation ($P < 3.4E-88$), and necrosis ($P < 7.2E-88$). The network 'inflammatory
234 disease' (score 35) (Figure 4B) shows pertinent significant biological processes
235 including organisation of collagen fibrils ($P < 3.7E-07$), fibrosis ($P < 2.6E-14$), rheumatoid
236 arthritis ($P < 3.6E-06$), angiogenesis ($P < 8.9E-09$), differentiation of bone ($P < 5E-06$),
237 inflammation of the joint ($P < 8.8E-07$) and cartilage development ($1.5E-07$).

238

239 To obtain an overview of pathways that the putative target mRNAs were involved in
240 the mRNAs derived from IPA were also input into the gene ontology (GO) tool TOPP
241 Gene and the biological processes summarised in REViGO and visualised using
242 Cytoscape (Figure 5 and Supplementary Table 4).

243

244

245 **DISCUSSION**

246 The global prevalence of knee OA is currently 5% and is projected to rise with an
247 increase in the ageing population [37]. Reports propose that there is an association
248 between ACL degeneration and subsequent knee OA, suggesting the importance of
249 ACL degradation and regeneration molecular mechanisms in OA pathogenesis [38].
250 There is also a strong correlation between ACL degeneration and subsequent knee
251 OA [12]. One potential mechanism capable of regulating global alterations to a
252 particular tissue is modification of sncRNA expression. To begin to elucidate the role
253 that they play in the global changes observed in the ACL during OA and understand
254 further the potential role of the ACL in arthritis, we undertook a non-biased approach
255 small RNA sequencing of ACLs from OA knee joints and compared these to our control
256 samples derived from non-OA knee joints. Whilst a study previously demonstrated DE
257 miRNAs in ACL [20], this is the first time that, to our knowledge, small RNA sequencing
258 has been used to interrogate both snoRNAs and miRNAs in an unbiased manner and
259 we identified unique OA dependant signatures.

260

261 There were 68 snoRNAs, 26 snRNAs and 90 miRNAs significantly different in ACLs
262 derived from OA knee joints and the OA status of the donor accounted for the principal
263 variability in the data. Additional bioinformatics was performed, to analyse the

264 biological processes and pathways affected by the differentially expressed miRNAs
265 and in addition, the putative mRNA targets of the differentially expressed miRNAs,
266 enhancing our understanding of the roles of the dysregulated miRNAs in OA
267 pathogenesis.

268

269 Several of DE miRNAs found in this study, including miR-29b, miR -335, let-7f, miR-
270 424, and miR-941 correlate to previously altered miRNAs in a study comparing
271 ruptured ACLs to diseased OA ACLs [20]. These miRNAs were found to be correlated
272 with cartilage development and remodelling, extracellular matrix homeostasis and
273 inflammatory response [20]. We have found other miRNAs associated with OA
274 including miR-206, miR-101, miR365, miR-29b and miR-29c, whose expression
275 altered in ACLs derived from OA joints [39-41]. Pathways identified by the DE miRNAs
276 with known functions in OA in other tissues included inflammation [42], proliferation of
277 chondrocytes [43], and fibrosis [44]. Canonical pathways identified have roles in OA
278 pathogenesis including senescence [45], fibrosis, TGF β signalling [46], retinoic acid
279 binding protein (RAR) activation [47] and peroxisome proliferator-activated
280 receptor/retinoid X receptor (PPAR/RXR) activation [48, 49].

281

282 To address the roles of miRNAs in diseased OA ACLs, their mRNA target genes
283 should also be taken into consideration. Therefore, in order to determine potential
284 mRNA targets of the DE miRNAs we used Target Filter in IPA to identify predicted
285 mRNA targets. We used conservative filters for the mRNAs identified by only choosing
286 highly conserved predicted mRNA targets for each miRNA and by choosing relevant
287 cell types to ACL tissue. We then undertook GO analysis and visualisation of the
288 significant biological processes effected with online tools. Using ToppGene, Revigo

289 and Cytoscape for visualisation, we showed an overview of the essential biological
290 processes these mRNA target genes were involved in, including extracellular matrix
291 organisation, epigenetic regulation, cell signalling, cell growth and proliferation. In IPA,
292 additional functions affected by these genes, known to have a role in OA pathogenesis
293 and therefore with a potential role in OA ACLs were highlighted including apoptosis
294 [50], fibrosis [44], inflammation of the joint [42], necrosis [51], organisation of collagen
295 fibrils [12], angiogenesis [52], differentiation of bone [53] and cartilage development
296 [54]. Canonical pathway analysis was also performed. We found that many pathways
297 enriched by the putative target genes were essential for OA pathogenesis, including
298 the 'osteoarthritis pathway'. The significant mRNA targets in this pathway included
299 those involved in inflammation (TNF, IL1, IL8), Wnt signalling (WNT3A, Frizzled,
300 TCF/LEF), TGF β and SMAD signalling (TGF β R2, SMAD1, -4, -5, -8), hypoxia (HIF1 α),
301 and mammalian target of rapamycin signalling (MTOR). Additionally downstream
302 targets of these signalling pathways with known roles in OA pathogenesis were
303 identified and included matrix metalloproteinase-3 [55], tissue inhibitor of
304 metalloproteinase-3 [56], and collagen X α 1 [57]. These findings indicate the potential
305 importance of these pathways in ACL degeneration associated with OA. Hepatic
306 fibrosis was the most significant canonical pathway identified from the putative
307 mRNAs together with the DE miRNAs in our study. Synovial fibrosis is often found in
308 OA [44] and fibrosis has previously been described in OA joints following ACL injury
309 [58]. Furthermore TGF β , one of the most significant upstream regulator in our mRNA
310 target gene analysis, is the master regulator of fibrosis [57]. Many TGF β -related genes
311 including TGF β 2, TGF β 3, TGF β R1, TGF β R2 and TGF β R3 were predicted targets of
312 the DE miRNAs including miR-98-5p, miR-101-3p, miR-128-5p, miR-136-3p, miR-17-
313 5p; strongly implicating it in the fibrosis evident in the diseased ACLs in OA.

314

315 Another class of snRNAs, snoRNAs, were altered in the OA ACLs in our study. This
316 conserved class of non-coding RNAs are principally characterised as guiding site-
317 specific post-transcriptional modifications in ribosomal RNA [59]. Furthermore
318 snoRNAs can modify and/or interact with additional classes of RNAs including other
319 snoRNAs, transfer RNAs and mRNAs [60]. A reliable modification site has been
320 assigned to 83% of the canonical snoRNAs, with 76 snoRNAs described as orphan,
321 meaning they act in an unknown or unique manner [61]. Novel functions reported for
322 snoRNAs including the modulation of alternative splicing [62], involvement in stress
323 response pathways, [63] and the modulation of mRNA 3'end processing [64]. Like
324 miRNAs, snoRNAs are emerging as important regulators of cellular function and
325 disease development [65], in part due to their ability to fine-tune the ribosome to
326 accommodate changing requirements for protein production during development,
327 normal function and disease [66] .

328

329 We have previously identified a role for snoRNAs in cartilage ageing and OA [24] and
330 their potential use as biomarkers for OA [27]. Furthermore, others identified that the
331 snoRNAs, SNORD38 and SNORD48, are significantly elevated in the serum of
332 patients developing cartilage damage a year following ACL injury and serum levels of
333 SNORD38 were greatly elevated in patients who develop cartilage damage after ACL
334 injury suggesting SNORD38 as a serum biomarker for early cartilage damage [67]

335

336 Interestingly, we found an increase in SNORD113 and SNORD114 in diseased OA
337 ACLs. These snoRNAs are located in imprinted human loci and may play a role in the
338 evolution and/or mechanism of epigenetic imprinting [61]. They belong to the C/D box

339 class of snoRNAs and most of the members of the box C/D family direct site-specific
340 2'-O-methylation of substrate RNAs. However, SNORD113 and SNORD114 differ
341 from C/D box snoRNAs in their tissue specific expression profiles (including in
342 fibroblasts, osteoblasts and chondrocytes [61] and the lack of complementarity to any
343 RNA. As a result, they are not predicted to guide to 2'O-methylation but have novel,
344 unknown roles [61]. Additionally SNORD113-1 functions as a tumour suppressor in
345 hepatic cell carcinoma by reducing cell growth and inactivating the phosphorylation of
346 ERK1/2 and SMAD2/3 in MAPK/ERK and TGF- β pathways [68]. We have previously
347 identified that SNORD113-1 is also increased in OA human knee cartilage but
348 reduced in ageing human knee cartilage, whilst SNORD114 increases in OA knee
349 cartilage [24].

350

351 SNORD72 was increased in diseased OA ACLs. In hepatocellular carcinoma, the
352 overexpression of SNORD72 was found to enhance cell proliferation, colony formation
353 and invasion by stabilising Inhibitor of differentiation (ID) genes which are a basic helix-
354 loop-helix (bHLH) transcription factors [69]. The ID family genes have been shown to
355 play a role in cell proliferation and angiogenesis [70]. The lack of a DNA binding
356 domain, results in inhibition of the binding of other transcription factors to DNA in a
357 dominant negative fashion [71]. The expression of some members of this family in
358 rheumatoid arthritis synovium suggests they may have a role in human inflammatory
359 disease [72]. Whilst the downstream signalling of snoRNAs is principally
360 unknown, snoRNAs regulate ribosome biogenesis [73]. However a subclass of
361 orphans do not have complimentary RNA sequences [74]. Mao Chet et al., found that
362 ribosome biogenesis was not affected following SNORD72 overexpression implying
363 it exerts functionality in other ways [69]. Therefore whilst some snoRNAs can regulate

364 the expression of RNAs [75], others can reduce the gene stability [74] or directly
365 activate or suppress enzymes [76]. Together our snoRNA findings indicate that
366 changes in ACL snoRNA expression could have important implications in knee OA
367 through both canonical and non-canonical roles.

368

369 Our study has a number of limitations due to availability of human ACL tissue. There
370 was also a mild imbalance between the sexes in the two groups with most of the OA
371 derived ACLs coming from males but all the control group being sourced from females.
372 In human tendon, we have previously demonstrated that males and females are
373 transcriptionally different and gene expression in aged cells moves in opposite
374 directions [26]. Ligament degeneration has also been demonstrated to be influenced
375 by lower concentrations of sex hormones in young female athletes [77]. Macroscopic
376 grading of tissues were not performed due to limited images of diseased OA ACL
377 samples, however images of control samples demonstrated healthy knee joint
378 cartilage with no signs of ACL degeneration. Finally, there were age discrepancies
379 between the two groups and so we cannot discount an age effect on sncRNAs
380 expression.

381

382 In conclusion, our study revealed alterations in a number of classes of snRNAs in ACL
383 tissues derived from patients with knee OA compared to apparently healthy ACLs from
384 non-OA joints. Our functional bioinformatic analyses suggests that the dysregulated
385 miRNAs may regulate cartilage development and remodelling, collagen biosynthesis
386 and degradation, ECM homeostasis and pathology by interacting with their targets.
387 Uniquely we also demonstrate that snoRNAs may also have a role in ACL

388 degeneration. Collectively, our study provides novel insight into the ACL related
389 sncRNA dysregulation in patients with OA.

390

391 **Competing interests**

392 The authors declare no competing interests.

393

394 **Acknowledgement**

395 Mandy Peffers funded through a Wellcome Trust Intermediate Clinical Fellowship
396 (107471/Z/15/Z). This work was also supported by Institute of Ageing and Chronic
397 disease (Comerford) and by the MRC and Versus Arthritis as part of the Medical
398 Research Council Versus Arthritis Centre for Integrated Research into
399 Musculoskeletal Ageing (CIMA) [MR/R502182/1]. The MRC Versus Arthritis Centre for
400 Integrated Research into Musculoskeletal Ageing is a collaboration between the
401 Universities of Liverpool, Sheffield and Newcastle. The authors would like to
402 acknowledge, Dr Pieter Emans, Maastricht University Orthopaedic surgeon for
403 collating OA diseased samples.

404

405 **Authors' contributions**

406 MP, EC and YAK designed and coordinated the study. TW collected the samples.
407 YF processed the samples for small RNA sequencing. MP and YA conducted the
408 statistical analysis and drafted the manuscript. All authors revised the draft critically
409 read and approved the final submitted manuscript.

410

411

412

413 **References**

- 414 1. Rumian, A.P., A.L. Wallace, and H.L. Birch, *Tendons and ligaments are*
415 *anatomically distinct but overlap in molecular and morphological features—a*
416 *comparative study in an ovine model*. *Journal of orthopaedic research*, 2007.
417 **25**(4): p. 458-464.
- 418 2. Woo, S.L.Y., et al., *Injury and Repair of Ligaments and Tendons*. *Annual*
419 *Review of Biomedical Engineering*, 2000. **2**(1): p. 83-118.
- 420 3. Gianotti, S.M., et al., *Incidence of anterior cruciate ligament injury and other*
421 *knee ligament injuries: A national population-based study*. *Journal of Science*
422 *and Medicine in Sport*, 2009. **12**(6): p. 622-627.
- 423 4. Robling, M.R., et al., *Time to talk? Patient experiences of waiting for clinical*
424 *management of knee injuries*. *Quality and Safety in Health Care*, 2009. **18**(2):
425 p. 141-146.
- 426 5. Cumps, E., et al., *Injury rate and socioeconomic costs resulting from sports*
427 *injuries in Flanders: data derived from sports insurance statistics 2003*. *British*
428 *journal of sports medicine*, 2008. **42**(9): p. 767-772.
- 429 6. Ali, N. and G. Rouhi, *Barriers to predicting the mechanisms and risk factors of*
430 *non-contact anterior cruciate ligament injury*. *The open biomedical*
431 *engineering journal*, 2010. **4**: p. 178.
- 432 7. Griffin, L.Y., et al., *Noncontact anterior cruciate ligament injuries: risk factors*
433 *and prevention strategies*. *JAAOS-Journal of the American Academy of*
434 *Orthopaedic Surgeons*, 2000. **8**(3): p. 141-150.
- 435 8. Kiapour, A. and M. Murray, *Basic science of anterior cruciate ligament injury*
436 *and repair*. *Bone and Joint Research*, 2014. **3**(2): p. 20-31.
- 437 9. Wurtzel, C.N., et al., *Pharmacological inhibition of myostatin protects against*
438 *skeletal muscle atrophy and weakness after anterior cruciate ligament tear*.
439 *Journal of Orthopaedic Research*, 2017.
- 440 10. Driban, J.B., et al., *Association of knee injuries with accelerated knee*
441 *osteoarthritis progression: data from the Osteoarthritis Initiative*. *Arthritis care*
442 *& research*, 2014. **66**(11): p. 1673-1679.
- 443 11. Barenus, B., et al., *Increased risk of osteoarthritis after anterior cruciate*
444 *ligament reconstruction: a 14-year follow-up study of a randomized controlled*
445 *trial*. *The American journal of sports medicine*, 2014. **42**(5): p. 1049-1057.
- 446 12. Hasegawa, A., et al., *Anterior cruciate ligament changes in the human knee*
447 *joint in aging and osteoarthritis*. *Arthritis & Rheumatism*, 2012. **64**(3): p. 696-
448 704.
- 449 13. Soriano-Arroquia, A., et al., *The functional consequences of age-related*
450 *changes in microRNA expression in skeletal muscle*. *Biogerontology*, 2016.
451 **17**(3): p. 641-654.

- 452 14. Goljanek-Whysall, K., D. Sweetman, and A.E. Münsterberg, *microRNAs in*
453 *skeletal muscle differentiation and disease*. Clinical science, 2012. **123**(11): p.
454 611-625.
- 455 15. Peffers, M., et al., *BIG tasks for small RNAs; a new class of rnas in the*
456 *pathogenesis of osteoarthritis*. Osteoarthritis and Cartilage, 2016. **24**: p. S372.
- 457 16. Balaskas, P., et al., *MicroRNA Profiling in Cartilage Ageing*. International
458 journal of genomics, 2017. **2017**.
- 459 17. Millar, N.L., et al., *MicroRNA29a regulates IL-33-mediated tissue remodelling*
460 *in tendon disease*. Nature communications, 2015. **6**: p. 6774.
- 461 18. Watts, A.E., et al., *MicroRNA29a treatment improves early tendon injury*.
462 Molecular Therapy, 2017. **25**(10): p. 2415-2426.
- 463 19. Xu, C., et al., *Integrated microRNA-mRNA analyses reveal OPLL specific*
464 *microRNA regulatory network using high-throughput sequencing*. Scientific
465 reports, 2016. **6**: p. 21580.
- 466 20. Li, B., et al., *Identification of differentially expressed microRNAs in knee*
467 *anterior cruciate ligament tissues surgically removed from patients with*
468 *osteoarthritis*. International journal of molecular medicine, 2017. **40**(4): p.
469 1105-1113.
- 470 21. Barter, M., C. Bui, and D. Young, *Epigenetic mechanisms in cartilage and*
471 *osteoarthritis: DNA methylation, histone modifications and microRNAs*.
472 Osteoarthritis and cartilage, 2012. **20**(5): p. 339-349.
- 473 22. Choudhuri, S., *Small noncoding RNAs: biogenesis, function, and emerging*
474 *significance in toxicology*. J Biochem Mol Toxicol, 2010. **24**(3): p. 195-216.
- 475 23. Peffers, M.J., X. Liu, and P.D. Clegg, *Transcriptomic signatures in cartilage*
476 *ageing*. Arthritis research & therapy, 2013. **15**(4): p. R98.
- 477 24. Peffers, M.J., et al., *snoRNA signatures in cartilage ageing and osteoarthritis*.
478 Osteoarthritis and Cartilage, 2018. **26**: p. S164.
- 479 25. Peffers, M.J., et al., *Transcriptome analysis of ageing in uninjured human*
480 *Achilles tendon*. Arthritis Res Ther, 2015. **17**: p. 33.
- 481 26. Pease, L.I., et al., *Cross platform analysis of transcriptomic data identifies*
482 *ageing has distinct and opposite effects on tendon in males and females*.
483 Scientific Reports, 2017. **7**(1): p. 14443.
- 484 27. Steinbusch, M.M., et al., *Serum snoRNAs as biomarkers for joint ageing and*
485 *post traumatic osteoarthritis*. Scientific Reports, 2017. **7**: p. 43558.
- 486 28. Martin, M., *Cutadapt removes adapter sequences from high-throughput*
487 *sequencing reads*. EMBnet. journal, 2011. **17**(1): p. 10-12.
- 488 29. Kim, D., et al., *TopHat2: accurate alignment of transcriptomes in the presence*
489 *of insertions, deletions and gene fusions*. Genome biology, 2013. **14**(4): p.
490 R36.

- 491 30. Anders, S., P.T. Pyl, and W. Huber, *HTSeq—a Python framework to work with*
492 *high-throughput sequencing data*. *Bioinformatics*, 2015. **31**(2): p. 166-169.
- 493 31. Anders, S. and W. Huber, *Differential expression analysis for sequence count*
494 *data* *Genome Biology*. 11: R106. doi: 10.1186/gb-2010-11-10-r106 View
495 *Article PubMed*. 2010, NCBI.
- 496 32. Benjamini, Y. and Y. Hochberg, *Controlling the false discovery rate: a*
497 *practical and powerful approach to multiple testing*. *Journal of the Royal*
498 *statistical society: series B (Methodological)*, 1995. **57**(1): p. 289-300.
- 499 33. Chen, J., et al., *ToppGene Suite for gene list enrichment analysis and*
500 *candidate gene prioritization*. *Nucleic acids research*, 2009. **37**(suppl_2): p.
501 W305-W311.
- 502 34. Supek, F., et al., *REVIGO summarizes and visualizes long lists of gene*
503 *ontology terms*. *PLoS one*, 2011. **6**(7): p. e21800.
- 504 35. Shannon, P., et al., *Cytoscape: a software environment for integrated models*
505 *of biomolecular interaction networks*. *Genome research*, 2003. **13**(11): p.
506 2498-2504.
- 507 36. Xia, J., et al., *MetaboAnalyst: a web server for metabolomic data analysis and*
508 *interpretation*. *Nucleic acids research*, 2009. **37**(suppl_2): p. W652-W660.
- 509 37. Hawker, G.A., *Osteoarthritis is a serious disease*. *Clin Exp Rheumatol*, 2019.
510 **37**(120): p. S3-S6.
- 511 38. Friel, N.A. and C.R. Chu, *The role of ACL injury in the development of*
512 *posttraumatic knee osteoarthritis*. *Clinics in sports medicine*, 2013. **32**(1): p. 1-
513 12.
- 514 39. Peffers, M., P. Balaskas, and A. Smagul, *Osteoarthritis year in review 2017:*
515 *genetics and epigenetics*. *Osteoarthritis and cartilage*, 2018. **26**(3): p. 304-
516 311.
- 517 40. Malemud, C.J., *MicroRNAs and osteoarthritis*. *Cells*, 2018. **7**(8): p. 92.
- 518 41. Endisha, H., et al., *The complex landscape of microRNAs in articular*
519 *cartilage: biology, pathology, and therapeutic targets*. *JCI insight*, 2018. **3**(17).
- 520 42. Lieberthal, J., N. Sambamurthy, and C.R. Scanzello, *Inflammation in joint*
521 *injury and post-traumatic osteoarthritis*. *Osteoarthritis and cartilage*, 2015.
522 **23**(11): p. 1825-1834.
- 523 43. Liu, Y., et al., *Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and*
524 *chondrocyte proliferation in osteoarthritis*. *Biochemical Journal*, 2018. **475**(22):
525 p. 3629-3638.
- 526 44. Remst, D.F., E.N. Blaney Davidson, and P.M. van der Kraan, *Unravelling*
527 *osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness*.
528 *Rheumatology*, 2015. **54**(11): p. 1954-1963.

- 529 45. Jeon, O.H., et al., *Senescent cells and osteoarthritis: a painful connection*.
530 The Journal of clinical investigation, 2018. **128**(4): p. 1229-1237.
- 531 46. Davidson Blaney, E., P. van der Kraan, and W. van den Berg, *TGF-beta and*
532 *osteoarthritis*. Osteoarthritis Cartilage, 2007. **15**: p. 597-604.
- 533 47. Zisakis, A., et al., *Expression of Retinoic Acid Receptor (RAR) α Protein in the*
534 *Synovial Membrane from Patients with Osteoarthritis and Rheumatoid*
535 *Arthritis*. International journal of biomedical science: IJBS, 2007. **3**(1): p. 46.
- 536 48. Li, X.-F., et al., *Functional role of PPAR- γ on the proliferation and migration of*
537 *fibroblast-like synoviocytes in rheumatoid arthritis*. Scientific reports, 2017.
538 **7**(1): p. 1-13.
- 539 49. Yang, H., et al., *CRISPR/Cas9-mediated genome editing efficiently creates*
540 *specific mutations at multiple loci using one sgRNA in Brassica napus*.
541 Scientific reports, 2017. **7**(1): p. 1-13.
- 542 50. Heraud, F., A. Heraud, and M. Harmand, *Apoptosis in normal and*
543 *osteoarthritic human articular cartilage*. Annals of the rheumatic diseases,
544 2000. **59**(12): p. 959-965.
- 545 51. Li, H., C. Chen, and S. Chen, *Posttraumatic knee osteoarthritis following*
546 *anterior cruciate ligament injury: Potential biochemical mediators of*
547 *degenerative alteration and specific biochemical markers*. Biomedical reports,
548 2015. **3**(2): p. 147-151.
- 549 52. Ashraf, S. and D.A. Walsh, *Angiogenesis in osteoarthritis*. Current opinion in
550 rheumatology, 2008. **20**(5): p. 573-580.
- 551 53. Ripmeester, E.G., et al., *Recent insights into the contribution of the changing*
552 *hypertrophic chondrocyte phenotype in the development and progression of*
553 *osteoarthritis*. Frontiers in bioengineering and biotechnology, 2018. **6**: p. 18.
- 554 54. Goldring, M.B. and K.B. Marcu, *Epigenomic and microRNA-mediated*
555 *regulation in cartilage development, homeostasis, and osteoarthritis*. Trends
556 in molecular medicine, 2012. **18**(2): p. 109-118.
- 557 55. Burrage, P.S., K.S. Mix, and C.E. Brinckerhoff, *Matrix metalloproteinases: role*
558 *in arthritis*. Front Biosci, 2006. **11**(1): p. 529-543.
- 559 56. Sahebjam, S., R. Khokha, and J.S. Mort, *Increased collagen and aggrecan*
560 *degradation with age in the joints of Timp3^{-/-} mice*. Arthritis & Rheumatism,
561 2007. **56**(3): p. 905-909.
- 562 57. Zhong, L., et al., *Correlation between gene expression and osteoarthritis*
563 *progression in human*. International journal of molecular sciences, 2016.
564 **17**(7): p. 1126.
- 565 58. Douglas, M., J. Hutchison, and A. Sutherland, *Anterior cruciate ligament*
566 *integrity in osteoarthritis of the knee in patients undergoing total knee*
567 *replacement*. Journal of Orthopaedics and Traumatology, 2010. **11**(3): p. 149.

- 568 59. Dieci, G., M. Preti, and B. Montanini, *Eukaryotic snoRNAs: a paradigm for*
569 *gene expression flexibility*. Genomics, 2009. **94**(2): p. 83-88.
- 570 60. Kishore, S., et al., *Insights into snoRNA biogenesis and processing from PAR-*
571 *CLIP of snoRNA core proteins and small RNA sequencing*. Genome biology,
572 2013. **14**(5): p. R45.
- 573 61. Jorjani, H., et al., *An updated human snoRNAome*. Nucleic acids research,
574 2016. **44**(11): p. 5068-5082.
- 575 62. Khanna, A. and S. Stamm, *Regulation of alternative splicing by short non-*
576 *coding nuclear RNAs*. rNA Biology, 2010. **7**(4): p. 480-485.
- 577 63. Michel, C.I., et al., *Small nucleolar RNAs U32a, U33, and U35a are critical*
578 *mediators of metabolic stress*. Cell metabolism, 2011. **14**(1): p. 33-44.
- 579 64. Huang, C., et al., *A snoRNA modulates mRNA 3' end processing and*
580 *regulates the expression of a subset of mRNAs*. Nucleic acids research, 2017.
581 **45**(15): p. 8647-8660.
- 582 65. Stepanov, G.A., et al., *Regulatory role of small nucleolar RNAs in human*
583 *diseases*. BioMed research international, 2015. **2015**.
- 584 66. Montanaro, L., D. Treré, and M. Derenzini, *Nucleolus, ribosomes, and cancer*.
585 The American journal of pathology, 2008. **173**(2): p. 301-310.
- 586 67. Zhang, L., et al., *Serum non-coding RNAs as biomarkers for osteoarthritis*
587 *progression after ACL injury*. Osteoarthritis and cartilage, 2012. **20**(12): p.
588 1631-1637.
- 589 68. Xu, G., et al., *Small nucleolar RNA 113-1 suppresses tumorigenesis in*
590 *hepatocellular carcinoma*. Molecular cancer, 2014. **13**(1): p. 216.
- 591 69. Mao, L.-H., et al., *LncRNA-LALR1 upregulates small nucleolar RNA*
592 *SNORD72 to promote growth and invasion of hepatocellular carcinoma*. Aging
593 (Albany NY), 2020. **12**(5): p. 4527.
- 594 70. Lyden, D., et al., *Id1 and Id3 are required for neurogenesis, angiogenesis and*
595 *vascularization of tumour xenografts*. Nature, 1999. **401**(6754): p. 670-677.
- 596 71. Benezra, R., et al., *A Negative Regulator of Helix-Loop-Helix DNA Binding*
597 *Proteins: Control of Terminal Myogenic Differentiation*. Annals of the New
598 York Academy of Sciences, 1990. **599**(1): p. 1-11.
- 599 72. Edhayan, G., et al., *Inflammatory properties of inhibitor of DNA binding 1*
600 *secreted by synovial fibroblasts in rheumatoid arthritis*. Arthritis research &
601 therapy, 2016. **18**(1): p. 87.
- 602 73. Gong, J., et al., *A pan-cancer analysis of the expression and clinical*
603 *relevance of small nucleolar RNAs in human cancer*. Cell reports, 2017. **21**(7):
604 p. 1968-1981.
- 605 74. Sharma, E., et al., *Global mapping of human RNA-RNA interactions*.
606 Molecular cell, 2016. **62**(4): p. 618-626.

- 607 75. Xing, Y.-H., et al., *SLERT regulates DDX21 rings associated with Pol I*
608 *transcription*. *Cell*, 2017. **169**(4): p. 664-678. e16.
- 609 76. Saprashvili, Z., et al., *The noncoding RNAs SNORD50A and SNORD50B bind*
610 *K-Ras and are recurrently deleted in human cancer*. *Nature genetics*, 2016.
611 **48**(1): p. 53.
- 612 77. Stijak, L., et al., *The influence of sex hormones on anterior cruciate ligament*
613 *rupture: female study*. *Knee Surgery, Sports Traumatology, Arthroscopy*,
614 2015. **23**(9): p. 2742-2749.

615

616

617

618

619 **Table 1.** Differentially expressed miRs with the highest and lowest log2 fold-change
620 when comparing from control versus diseased OA anterior cruciate ligament (ACL).

621

miR	Log2 change	fold- FDR adjusted p-values
Genes with increased expression in diseased OA ACL		
hsa-miR-5100	3.75	6.2E-07
hsa-miR-31-5p	3.14	6.9E-15
hsa-miR-129-5p	2.42	4.0E-03
hsa-miR-144-3p	2.41	3.5E-04
hsa-miR-486-5p	2.33	3.2E-04
hsa-miR-370-3p	2.32	1.4E-06
hsa-miR-543	2.20	6.3E-03
hsa-miR-4521	2.19	5.1E-04
hsa-miR-493-5p	2.17	6.7E-04
hsa-miR-411-3p	2.16	3.9E-03
Genes with reduced expression in control ACL		
hsa-miR-206	-6.13	1.9E-06
hsa-miR-12136	-4.35	3.3E-18
hsa-miR-3182	-3.20	3.8E-10
hsa-miR-101-5p	-2.22	9.6E-03
hsa-miR-338-3p	-2.08	1.5E-02
hsa-miR-335-5p	-2.03	7.3E-03
hsa-miR-190b-5p	-1.98	2.5E-03
hsa-miR-29c-3p	-1.89	1.1E-02
hsa-miR-103a-5p	-1.86	3.7E-06
hsa-miR-30b-5p	-1.81	1.7E-02

622

623

624

625

626

627

628 **Table 2.** Small-non coding RNAs (small nucleolar RNAs (snoRNAs) and small nuclear
 629 RNA (sncRNA) identified as differentially expressed between control and anterior
 630 cruciate ligaments (ACLs) derived from osteoarthritic joints.

Name	Family	Action	Log2 fold-change	FDR adjusted p-value	Higher
SNORD114	C/D BOX	Site-specific 2'-O-methylation	3.60	4.7E-07	OA ACL
SNORD113	C/D BOX	Site-specific 2'-O-methylation	2.85	9.8E-05	OA ACL
RNU6	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	2.85	4.8E-03	OA ACL
SNORD72	C/D BOX	Site-specific 2'-O-methylation	1.83	4.2E-02	OA ACL
RNVU1-19	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	1.58	4.8E-02	OA ACL
RNU7-19P	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	-7.61	4.0E-07	Control ACL
RNU4-59P	Spliceosome	Complex of snRNA and protein subunits that removes introns from a transcribed pre-mRNA	-4.90	1.4E-33	Control ACL
SNORA36B	H/ACA box	H/ACA family of pseudouridylation guide snoRNAs	-4.25	2.7E-06	Control ACL
SNORA53	H/ACA box	H/ACA family of pseudouridylation guide snoRNAs	-3.68	5.1E-15	Control ACL
SNORA73B	H/ACA box	H/ACA family of pseudouridylation guide snoRNAs	-3.61	3.9E-05	Control ACL

631

632

633 **Table 3.** Top canonical pathways for target mRNAs of differentially expressed miRNAs
634 in diseased OA anterior cruciate ligaments (ACLs).

635	Name	p-value	Overlap
636	Hepatic Fibrosis Signalling Pathway	1.62E-33	15.8 %
637			
638	Hepatic Fibrosis/Hepatic Stellate Cell Activation	3.06E-32	23.1 %
639			
640	Cardiac Hypertrophy Signalling	1.28E-28	12.3 %
641			
642	Colorectal Cancer Metastasis Signalling	1.97E-27	17.4 %
643			
644	Role of Macrophages, Fibroblasts and Endothelial Cells	2.32E-27	15.4 %
645			

646

647 **Table 4.** Top upstream regulators of differentially expressed miRNAs in diseased OA
648 anterior cruciate ligaments (ACLs).

649	Name	p-value
650	Tumour necrosis factor	1.31E-101
651	Transforming growth factor B1	8.50E-83
652	lipopolysaccharide	1.14E-81
653	Interleukin 1B	1.45E-77
654	tretinoin	9.26E-77

Figure legends

Figure 1. Overview of HiSeq transcriptomics data between control and diseased osteoarthritic (OA) human anterior cruciate ligament (ACL). A. Categories of RNAs identified in control and diseased OA ACL B) Principle component analysis revealed that small non-coding RNAs (sncRNA) between control and diseased ACL were distinctly grouped. C) Volcano plot demonstrate significant (FDR< 0.05) differentially expressed sncRNAs (red dots) with a fold-change of 1.4. D. Heatmap representation of the small non-coding RNA reads from control to OA ACL. Columns refer to the control and OA ACL samples and rows of miRNAs identified with their Ensembl identification. Heatmap was generated using log-transformed normalised read counts, normalisation was performed by EdgeR's trimmed mean of M values. The colour of each entry is determined by the number of reads, ranging from yellow (positive values) to red (negative values).

Figure 2. Ingenuity Pathway Analysis (IPA) derived functions of differentially expressed microRNAs in diseased osteoarthritic (OA) anterior cruciate ligament (ACL). A. IPA identified that cellular functions differentiation of muscle, inflammation, proliferation, cell viability and fibrosis were associated with the differentially expressed microRNAs. Figures are graphical representations between molecules identified in our data in their respective networks. Red nodes, upregulated in OA, and green nodes, downregulated gene expression in OA. Intensity of colour is related to higher fold-change. Legends to the main features in the networks are shown. Functions colour is dependent on whether it is predicted to be activated or inhibited. B. Top network identified with canonical pathways overlaid for fibrosis, senescence, TGF β signalling, RAR activation and PPAR/RXR activation.

Figure 3. Osteoarthritis pathway targeted by predicted mRNA. The canonical pathway for osteoarthritis signalling was highly ranked ($p=2.33 \times 10^{-23}$) using target mRNAs identified in Ingenuity Pathway Analysis (IPA) TargetsCan from the differentially expressed miRNAs in diseased anterior cruciate ligaments (ACLs) derived from OA patients. The pathway was generated using IPA.

Figure 4. Top-scoring networks derived from the 529 putative mRNAs differentially expressed in anterior cruciate ligaments (ACLs) derived from osteoarthritic (OA) joints. Ingenuity pathway analysis (IPA) identified A. 'Cellular development, movement and genes expression' with a scores of 41. (B) 'Inflammatory disease, organismal injuries and abnormalities' with a score of 35 and within this network are molecules linked to their respective canonical pathways. Both are overlaid with pertinent significant biological functions contained in the gene sets. Figures are graphical representations between molecules identified in our data and predicted mRNA targets in their respective networks. Green nodes, downregulated in ACLs from OA joints; red nodes, upregulated gene expression in ACLs from OA joints. Intensity of colour is related to higher fold-change. Key to the main features in the networks is shown.

Figure 5. Gene ontology (GO) biological processes associated with dysregulated microRNAs targets were identified following TargetScan filter module using IPA. GO terms for biological process (FDR < 0.05) were summarized with ToppGene and visualised using REViGO and Cytoscape. Boxes represent the main clusters of biological processes that were significantly influenced by dysregulated micrRNAs between control and diseased osteoarthritic (OA) anterior cruciate ligaments (ACLs).

Supplementary Figures and Tables:

Supplementary Figure 1. Age groups between control anterior cruciate ligament (ACL) samples and diseased OA ACL samples.

Supplementary Figure 2. Heatmap representation of the differentially expressed snoRNAs and sncRNAs small non-coding RNA reads from control to OA anterior cruciate ligament (ACL)

Supplementary Table 1. Donors' age, gender and ethnicity information.

Supplementary Table 2. Differentially expressed sncRNAs between control and OA anterior cruciate ligament (ACL) samples with FDR<0.05 and reads greater than 10 counts per million (CPM).

Supplementary Table 3. Ingenuity Pathway Analysis (IPA) of differentially expressed microRNAs target genes between control and OA anterior cruciate ligament (ACL) and IPA of mRNA core analysis of putative mRNAs targets

Supplementary Table 4. Gene ontology (GO) of the top biological processes gene ontology of putative mRNA targets between control and OA anterior cruciate ligament (ACL) summarised in REViGO tool.




Figure 1.





Figure 2.




Figure 3.




Figure 4.




Figure 5.